

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* MCHUGH JAMES			2. Date of Event Requiring Statement (Month/Day/Year) 12/06/2021		3. Issuer Name and Ticker or Trading Symbol EXELON CORP [EXC]		
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ EVP & Chief Commercial Officer			5. If Amendment, Date of Original Filed (Month/Day/Year)	
10 S DEARBORN STREET 54TH FLOOR						6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	
(Street)	(City)	(State)	(Zip)				
CHICAGO	IL	60603					
(City)	(State)	(Zip)					

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	25,598	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Restricted Stock Unit Award (02/04/2019)	(1)	(1)	Common stock	4,275 ⁽¹⁾	(1)	D	
Restricted Stock Unit Award (01/27/2020)	(2)	(2)	Common stock	8,301 ⁽²⁾	(2)	D	
Restricted Stock Unit Award (01/25/2021)	(3)	(3)	Common stock	13,068 ⁽³⁾	(3)	D	
Restricted Stock Unit Award (04/05/2021)	(4)	(4)	Common stock	20,318 ⁽⁴⁾	(4)	D	
Deferred Phantom Shares	(5)	(5)	Common stock	2,175 ⁽⁵⁾	(5)	D	

Explanation of Responses:

1. Remaining 1/3 increment of annual restricted stock unit (RSU) award granted in February, 2019 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation & Leadership Development Committee's January or February meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
2. Remaining 2/3 increment of annual RSU award granted in January, 2020 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation & Leadership Development Committee's January or February meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
3. Annual RSU award granted in January 2021 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation & Leadership Development Committee's January or February meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
4. Restricted stock unit award granted pursuant to the Exelon LTI plan. All shares will cliff vest on April 5, 2025. Award balance accrue additional units through automatic dividend reinvestment which will vest on the same schedule as the underlying award.
5. Phantom share equivalents held as of November 30, 2021 representing units held in the Exelon stock fund in a multi-fund, non-qualified deferred compensation plan. The Exelon stock fund is a unitized fund that consists of Exelon common stock and short term investments. Units of the fund will be settled upon the reporting person's separation from the company for any reason. Units will be settled in cash. Units are acquired through regular periodic contributions, company matching contributions and the reinvestment of dividend equivalents. The balance of phantom share equivalents may fluctuate due to periodic changes in the fund composition.

Elizabeth M. Hensen, Attorney-in-Fact for James McHugh 12/14/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

EXELON CORPORATION
Section 16 Reporting Power of Attorney

The undersigned hereby constitutes and appoints each of Carter C. Culver, Elizabeth M. Hensen or Tom Boin signing singly, the undersigned's true and

- (1) execute for and on behalf of the undersigned, in the undersigned director of Exelon Corporation ("*Exelon*"), all reports to be filed under Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (including EDGAR Form ID, Forms 3, 4, and 5 and any successor forms)
- (2) do and perform any and all acts for and on behalf of the undersigned as may be desirable to complete and execute any such Section 16 Report or amendment or amendments thereto, and timely file such report or amendment with the Securities and Exchange Commission and any stock exchange or similar authority
- (3) take any other action of any type whatsoever in connection with the duties of such attorney-in-fact, may be of benefit to, in the best interests of the undersigned, it being understood that the documents executed by or on behalf of the undersigned pursuant to this Power of Attorney shall be in conformity with the terms and conditions as such attorney-in-fact may approve in such

The undersigned hereby grants to each such attorney-in-fact full power and authority to do any and every act and thing whatsoever requisite, necessary, or proper to carry out the rights and powers herein granted, as fully to all intents and purposes as he or she could do if personally present, with full power of substitution or replacement, and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute, may do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving the undersigned, are not assuming, nor is Exelon assuming, any of the obligations of the undersigned to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned ceases to file Section 16 Reports with respect to the undersigned's holdings of and transactions with respect to the securities of Exelon, unless earlier revoked by the undersigned in a signed written instrument.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be signed and sealed this day of December 2021.



By: _____

Name: James McHugh
